TrialThe oncologist2018

FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.

Lauretta Odogwu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.